Ultragenyx Pharmaceutical, Inc. Forecast, price target & analysts
Ultragenyx Pharmaceutical, Inc. Target price 2026 - Analyst rating & recommendation
Ultragenyx Pharmaceutical, Inc. Classifications & Recommendation
Ultragenyx Pharmaceutical, Inc. Price Target
| Target Price | $24.48 |
| Price | $15.22 |
| Potential |
60.84%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Ultragenyx Pharmaceutical, Inc. 2027 .
The average Ultragenyx Pharmaceutical, Inc. target price is $24.48.
This is
60.84%
register free of charge
$38.85
155.26%
register free of charge
$16.16
6.18%
register free of charge
|
|
| A rating was issued by 26 analysts: 23 Analysts recommend Ultragenyx Pharmaceutical, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ultragenyx Pharmaceutical, Inc. stock has an average upside potential 2027 of
60.84%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 673.00 | 776.71 |
| 20.13% | 15.41% | |
| EBITDA Margin | -78.31% | -49.90% |
| 17.30% | 36.28% | |
| Net Margin | -85.44% | -54.79% |
| 15.91% | 35.87% |
21 Analysts have issued a sales forecast Ultragenyx Pharmaceutical, Inc. 2026 . The average Ultragenyx Pharmaceutical, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Ultragenyx Pharmaceutical, Inc. EBITDA forecast 2026. The average Ultragenyx Pharmaceutical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Ultragenyx Pharmaceutical, Inc. Analysts have issued a net profit forecast 2026. The average Ultragenyx Pharmaceutical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.83 | -4.32 |
| 7.31% | 25.90% | |
| P/E | negative | |
| EV/Sales | 3.03 |
22 Analysts have issued a Ultragenyx Pharmaceutical, Inc. forecast for earnings per share. The average Ultragenyx Pharmaceutical, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ultragenyx Pharmaceutical, Inc....
Current Ultragenyx Pharmaceutical, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Sep 21 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 21 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Sep 21 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 21 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 17 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
